Analysts: UCB on steam for record sales

Based on the analyst expectation both the revenue and the net profit would be on all time high levels. For this year the consensus of the revenue equals 4,05 billion euros. The expectations would mean a record revenue for the company. This is slightly more than the revenue over 2015 of 3,88 billion euros.

Historical revenues and results UCB plus taxations 2016

For 2016 the analysts expect a record net profit of 537 million euros. For this year most of the analysts expect a profit per share of 2,85 euros. Based on this the price/earnings-ratio equals 25,71.

Per share a dividend of 1,26 euros is expected. The dividend yield consequently equals 1,72 percent. The average dividend of the pharmaceutical company equals a rather low percent.

Most recent target prices around 78 euros

UCB is being covered by 14 analysts (only based on fundamental analysis). The average target price for the stock is at 80,58 euros. This is around 10 percent more than the current stock price of 73,28 euros. The 3 most recent recommendations for the Belgian company were provided by Berenberg (hold, 77,00 euros), JP Morgan (buy, 79,00 euros) and Barclays (hold, without target price).

Based on the number of outstanding shares UCB 's market capitalization equals 13,8 billion euros.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.